ITGB4

Across TCGA pan-cancer cohorts, ITGB4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITGB4 data layer compared with 20 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ITGB4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ITGB4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where ITGB4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.701	1.000	.001	15	view →
CCRCC	OS	Median	III,IV	0.985	0.237	.017	13	view →
LUAD	OS	Quartile	II,III,IV	0.331	0.866	.010	8	view →
UCEC	OS	Median	II,III,IV	1.000	0.620	.011	6	view →
PDAC	OS	Tertile	III,IV	0.682	0.919	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITGB4–GBM (OS)

Open the GBM breakdown →